Lexicon Pharmaceuticals Inc. held its annual meeting of stockholders on June 2, 2025. During the meeting, stockholders approved several proposals. The election of Class I Directors, including Raymond Debbane and Ivan H. Cheung, was confirmed. An amendment to the company's Sixth Amended and Restated Certificate of Incorporation, allowing for a reverse split of common stock at a ratio within a range of 1-for-10 to 1-for-50, was approved. Additionally, the appointment of Ernst & Young LLP as the company's independent auditors for the fiscal year ending December 31, 2025, was ratified and approved.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.